Boston Scientific (NYSE:BSX) Cut to Market Perform at Oppenheimer

Oppenheimer lowered shares of Boston Scientific (NYSE:BSX) from an outperform rating to a market perform rating in a research note issued to investors on Thursday, Marketbeat Ratings reports.

Several other brokerages also recently issued reports on BSX. Raymond James Financial reiterated an “outperform” rating and issued a $57.00 target price (down from $78.00) on shares of Boston Scientific in a research note on Thursday, July 30th. UBS Group lowered their price target on Boston Scientific from $74.00 to $67.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Needham & Company LLC dropped their price objective on Boston Scientific from $57.00 to $48.00 and set a “buy” rating on the stock in a research note on Wednesday. Evercore cut their price objective on Boston Scientific from $65.00 to $52.00 and set an “outperform” rating for the company in a research report on Wednesday, October 7th. Finally, TD Cowen reissued a “buy” rating and set a $56.00 target price (down from $61.00) on shares of Boston Scientific in a report on Tuesday, October 20th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $61.43.

Boston Scientific Stock Performance

Shares of BSX stock opened at $41.93 on Thursday. The stock has a market cap of $60.77 billion, a P/E ratio of 17.77, a P/E/G ratio of 1.03 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a fifty day moving average price of $44.78 and a two-hundred day moving average price of $56.88. Boston Scientific has a one year low of $39.57 and a one year high of $105.65.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting analysts’ consensus estimates of $0.73. The company had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The company’s quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.75 EPS. As a group, equities analysts predict that Boston Scientific will post 3.17 EPS for the current year.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney bought 186,240 shares of the stock in a transaction dated Monday, August 3rd. The shares were bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the purchase, the chief executive officer owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the acquisition, the director owned 17,160 shares in the company, valued at $816,644.40. The trade was a 13.94% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 189,522 shares of company stock valued at $9,157,810. Corporate insiders own 0.34% of the company’s stock.

Institutional Trading of Boston Scientific

Institutional investors have recently added to or reduced their stakes in the company. Clal Insurance Enterprises Holdings Ltd bought a new stake in Boston Scientific during the first quarter valued at $28,000. Cassaday & Co Wealth Management LLC bought a new stake in shares of Boston Scientific during the 1st quarter valued at about $32,000. Measured Wealth Private Client Group LLC boosted its position in shares of Boston Scientific by 244.9% during the 1st quarter. Measured Wealth Private Client Group LLC now owns 545 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 387 shares in the last quarter. Kelleher Financial Advisors acquired a new stake in Boston Scientific during the second quarter worth approximately $25,000. Finally, Nvwm LLC grew its stake in Boston Scientific by 526.2% during the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 542 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded third-quarter earnings expectations, while management continues to support its long-term growth strategy. An eight-day cyber outage reduced quarterly sales by approximately $150 million, suggesting some of the impact may be temporary. Boston Scientific: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Some analysts still see upside: Robert W. Baird raised its price target to $51, while UBS, BTIG Research and Sanford C. Bernstein retained buy or outperform-equivalent ratings, although each lowered its target. Analysts Revise Forecasts After Q3 Results
• Neutral Sentiment: Barclays and Wells Fargo both maintain equal-weight ratings with $45 price targets, indicating limited expected upside from current levels and a wait-and-see stance.
• Negative Sentiment: Boston Scientific cut its fiscal 2026 guidance below analyst expectations, and its fourth-quarter outlook points to weaker sales. Management expects full-year organic revenue growth of about 4%, while analysts see growth challenges extending into 2027. BSX Q3 Earnings Call Flags Growth Challenges
• Negative Sentiment: The cyber incident, weakness in electrophysiology and WATCHMAN heart-device products, and pricing pressure in China are raising concerns about near-term revenue growth and execution. Boston Scientific Faces Cyber Incident and Product Pressures
• Negative Sentiment: Several firms downgraded the stock, including TD Cowen, JPMorgan, Oppenheimer and Needham. TD Cowen cut its rating to hold and reduced its target from $56 to $46, while Zacks added BSX to its Strong Sell list. New Strong Sell Stocks for October 30th
• Negative Sentiment: Relative to Intuitive Surgical, Boston Scientific is viewed as having weaker earnings momentum and less attractive near-term growth, adding competitive pressure to the investment case. Intuitive Surgical vs. Boston Scientific

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.